Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Fatigue and IL28B[original query] |
---|
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver international : official journal of the International Association for the Study of the Liver 2015 Feb 35 (2): 417-21. Zeuzem Stefan, Dufour Jean-François, Buti Maria, Soriano Vicente, Buynak Robert J, Mantry Parvez, Taunk Jawahar, Stern Jerry O, Vinisko Richard, Gallivan John-Paul, Böcher Wulf, Mensa Federico J, |
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 2014 Aug 384 (9941): 403-13. Jacobson Ira M, Dore Gregory J, Foster Graham R, Fried Michael W, Radu Monica, Rafalsky Vladimir V, Moroz Larysa, Craxi Antonio, Peeters Monika, Lenz Oliver, Ouwerkerk-Mahadevan Sivi, De La Rosa Guy, Kalmeijer Ronald, Scott Jane, Sinha Rekha, Beumont-Mauviel Mar |
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 2014 Aug 384 (9941): 414-26. Manns Michael, Marcellin Patrick, Poordad Fred, de Araujo Evaldo Stanislau Affonso, Buti Maria, Horsmans Yves, Janczewska Ewa, Villamil Federico, Scott Jane, Peeters Monika, Lenz Oliver, Ouwerkerk-Mahadevan Sivi, De La Rosa Guy, Kalmeijer Ronald, Sinha Rekha, Beumont-Mauviel Mar |
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England journal of medicine 2014 Jan 370 (3): 211-21. Sulkowski Mark S, Gardiner David F, Rodriguez-Torres Maribel, Reddy K Rajender, Hassanein Tarek, Jacobson Ira, Lawitz Eric, Lok Anna S, Hinestrosa Federico, Thuluvath Paul J, Schwartz Howard, Nelson David R, Everson Gregory T, Eley Timothy, Wind-Rotolo Megan, Huang Shu-Pang, Gao Min, Hernandez Dennis, McPhee Fiona, Sherman Diane, Hindes Robert, Symonds William, Pasquinelli Claudio, Grasela Dennis M, |
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology (Baltimore, Md.) 2016 Jan . Kwo Paul, Gitlin Norman, Nahass Ronald, Bernstein David, Etzkorn Kyle, Rojter Sergio, Schiff Eugene, Davis Mitchell, Ruane Peter, Younes Ziad, Kalmeijer Ronald, Sinha Rekha, Peeters Monika, Lenz Oliver, Fevery Bart, De La Rosa Guy, Scott Jane, Witek Jam |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: